Neuphoria Therapeutics Inc. (NEUP) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

42/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

70

Undervalued

Momentum

18

Strong Down

Sentiment

48

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Spyridon Papapetropoulos
Listed since: Dec 16, 2021
Employees: 8

Market position

Volume: 179.7K; 1.19× average
Average volume: 151.03K; Average daily volume
Market cap: 21.13M USD
Beta: 0.75; Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: -9.84M USD
EV / EBITDA: 80.75×
Earnings yield: -3.21%
Free cash flow yield: 670.23%

Profitability & efficiency

Return on equity: -1.28%
Return on assets: -0.85%
Return on invested capital: -1.34%

Financial health

Current ratio: 3.56×
Altman Z-score: -6.08
Piotroski F-score: 4 of 9

Earnings

EPS beat rate: 60%; 6 beats, 4 misses, 0 met estimates
Average EPS surprise: -5.11%; 10 comparable reports
Latest EPS result: -0.09; Estimate -0.56 · Beat by 83.93%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$7.00

79.03% upside

Past 12 months12-month forecastHigh $7.00Average $7.00Low $7.00

Recent analyst actions

2 institutions

Maxim GroupmaintainBuySep 11, 2025

NEUP news

prnewswire.comAug 4, 2026

Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

Read source

globenewswire.comJul 30, 2026

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a…

Read source

prnewswire.comJul 29, 2026

Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

Read source

globenewswire.comJul 28, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLC

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a…

Read source

gurufocus.comJul 24, 2026

NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) and Scancell Holdings plc. Upon closing

Read source